First Disclosures in Molecular Cancer Therapeutics present drugs for the first time in published literature, accompanied by pertinent translational investigations. Submissions are assessed based on ...

Publishing in July 2025 to coincide with the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning, the series will continue through December 2025! Technological ...

1State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

1Hunan Key Laboratory of Skin Cancer and Psoriasis, Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China ...

1Department of Pediatrics III, University Children’s Hospital Essen, University of Duisburg-Essen, Essen, Germany. 2Department of Otorhinolaryngology & Head/Neck Surgery, University Hospital ...

1Key Laboratory of Dunhuang Medicine and Transformation at Provincial and Ministerial Level, Gansu University of Chinese Medicine, Lanzhou, China. 2Provincial-Level Key Laboratory for Molecular ...

1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2Abramson Cancer Center and Abramson Family Cancer Research Institute, University of ...

1Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ...

Major Finding: PCSK9 regulates cholesterol uptake and controls the trajectory of metastasis to secondary organs in pancreatic ductal adenocarcinoma (PDAC). Concept: Cholesterol uptake supports ...

1Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Katherine K. Barnett, Center for Biologics Evaluation and Research, ...

Major Finding: Serotonin transporter depletes intratumoral serotonin which dampens CD8 + T-cell antitumor immunity. Concept: Serotonin transporter inhibition with SSRIs drives T-cell antitumor ...